# Anti-Thrombotic Activities of Veratramine via Inhibiting Platelet Aggregation and FIIa/FXa

## TL;DR

Veratramine, a compound from lily plants, shows promise in preventing harmful blood clots by inhibiting key clotting factors and platelet activity, potentially offering a safer alternative to current anticoagulants.

## Contribution

Veratramine's novel dual inhibition of thrombin and FXa, along with its suppression of fibrin polymerization and platelet reactivity, is newly characterized.

## Key findings

- Veratramine prolongs coagulation times and inhibits thrombin and FXa enzymatic activities.
- It reduces platelet aggregation and modulates fibrin clot formation in inflammatory conditions.
- Veratramine lowers the PAI-1/t-PA ratio in endothelial cells, supporting natural clot breakdown.

## Abstract

Vascular inflammation and blood clotting problems contribute to many serious diseases like sepsis and heart conditions, causing tissue damage and poor outcomes. This study explored whether veratramine, a natural compound from certain lily plants known for other health benefits like lowering blood pressure, could help prevent harmful blood clots. Using lab tests on human blood cells and experiments in mice, we found that veratramine safely slows down key steps in blood clotting, reduces platelet clumping, and supports the body’s natural clot-breaking process, especially when inflammation triggers clotting. Importantly, it works at safe doses without harming cells. These results suggest veratramine could be developed into a new, plant-based medicine to protect blood vessels and treat clotting-related illnesses, potentially offering fewer side effects than current drugs and benefiting patients worldwide by improving outcomes in inflammatory and heart diseases.

Background: There is growing interest in plant-derived compounds for managing vascular diseases. Veratramine (VRT), a steroidal alkaloid isolated from plants of the Veratrum genus, exhibits diverse biological effects such as antihypertensive, analgesic, and antitumor activities, yet its influence on hemostasis and thrombus formation has not been characterized. This investigation sought to determine whether VRT exerts anticoagulant effects using integrated in vitro and murine models. Methods: VRT’s anticoagulant profile was comprehensively evaluated using integrated biochemical, cellular, and murine models, including clotting time assays (aPTT/PT), chromogenic enzymatic assays, fibrin polymerization analysis, platelet aggregometry, and endothelial modulation of PAI-1/t-PA under inflammatory conditions. Results: VRT treatment significantly prolonged both intrinsic and extrinsic coagulation times, directly inhibited enzymatic activities of thrombin and FXa, and attenuated their generation by endothelial cells. Additionally, VRT interfered with fibrin clot formation and diminished agonist-induced platelet aggregation. Ex vivo coagulation analyses confirmed its anticoagulant action, while endothelial studies revealed a reduced PAI-1/t-PA ratio following VRT exposure. Conclusions: These data establish VRT as possessing novel direct dual inhibition of thrombin and FXa alongside suppression of fibrin polymerization, platelet reactivity, and PAI-1 expression—positioning it as a promising multifunctional anticoagulant agent. While preclinical murine models preclude direct clinical translation absent pharmacokinetic data, these findings warrant further mechanistic and translational investigation.